Literature DB >> 8085687

The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study.

N A Shadick1, C B Phillips, E L Logigian, A C Steere, R F Kaplan, V P Berardi, P H Duray, M G Larson, E A Wright, K S Ginsburg, J N Katz, M H Liang.   

Abstract

OBJECTIVE: To ascertain the prevalence of and risk factors for long-term sequelae from acute Lyme disease.
DESIGN: Population-based, retrospective cohort study.
SETTING: A coastal region endemic for Lyme disease. PARTICIPANTS: Patients with a history of Lyme disease who were previously treated with antibiotics were compared with randomly selected controls. MEASUREMENTS: A standardized physical examination, health status measure (Short Form 36), psychometric test battery, and serologic analysis.
RESULTS: Compared with the control group (n = 43), the Lyme group (n = 38; mean duration from disease onset to study evaluation, 6.2 years) had more arthralgias (61% compared with 16%; P < 0.0001); distal paresthesias (16% compared with 2%; P = 0.03); concentration difficulties (16% compared with 2%; P = 0.03); and fatigue (26% compared with 9%; P = 0.04), and they had poorer global health status scores (P = 0.04). The Lyme group also had more abnormal joints (P = 0.02) and more verbal memory deficits (P = 0.01) than did the control group. Overall, 13 patients (34%; 95% CI, 19% to 49%) had long-term sequelae from Lyme disease (arthritis or recurrent arthralgias [n = 6], neurocognitive impairment [n = 4], and neuropathy or myelopathy [n = 3]). Compared with controls, patients who had long-term sequelae had higher IgG antibody titers to the spirochete (P = 0.03) and received treatment later (34.5 months compared with 2.7 months; P < 0.0001).
CONCLUSIONS: Persons with a history of Lyme disease have more musculoskeletal impairment and a higher prevalence of verbal memory impairment when compared with those without a history of Lyme disease. Our findings suggest that disseminated Lyme disease may be associated with long-term morbidity.

Entities:  

Mesh:

Year:  1994        PMID: 8085687     DOI: 10.7326/0003-4819-121-8-199410150-00002

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  63 in total

1.  Human risk of infection with Borrelia burgdorferi, the Lyme disease agent, in eastern United States.

Authors:  Maria A Diuk-Wasser; Anne Gatewood Hoen; Paul Cislo; Robert Brinkerhoff; Sarah A Hamer; Michelle Rowland; Roberto Cortinas; Gwenaël Vourc'h; Forrest Melton; Graham J Hickling; Jean I Tsao; Jonas Bunikis; Alan G Barbour; Uriel Kitron; Joseph Piesman; Durland Fish
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

2.  Lyme disease: Is it or is it not?

Authors:  Bl Johnston; Jm Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-11       Impact factor: 2.471

3.  CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease Syndrome: a Prospective Clinical Cohort Study.

Authors:  John N Aucott; Mark J Soloski; Alison W Rebman; Lauren A Crowder; Lauren J Lahey; Catriona A Wagner; William H Robinson; Kathleen T Bechtold
Journal:  Clin Vaccine Immunol       Date:  2016-09-06

4.  Psychiatric comorbidity and other psychological factors in patients with "chronic Lyme disease".

Authors:  Afton L Hassett; Diane C Radvanski; Steven Buyske; Shantal V Savage; Leonard H Sigal
Journal:  Am J Med       Date:  2009-09       Impact factor: 4.965

Review 5.  The immune response to infectious diseases of the central nervous system: a tenuous balance.

Authors:  A R Pachner
Journal:  Springer Semin Immunopathol       Date:  1996

Review 6.  Chronic Lyme disease.

Authors:  Paul M Lantos
Journal:  Infect Dis Clin North Am       Date:  2015-06       Impact factor: 5.982

Review 7.  Chronic Lyme disease: a review.

Authors:  Adriana Marques
Journal:  Infect Dis Clin North Am       Date:  2008-06       Impact factor: 5.982

8.  Pre-treatment and post-treatment assessment of the C(6) test in patients with persistent symptoms and a history of Lyme borreliosis.

Authors:  R V Fleming; A R Marques; M S Klempner; C H Schmid; L G Dally; D S Martin; M T Philipp
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-08       Impact factor: 3.267

9.  Proof that chronic lyme disease exists.

Authors:  Daniel J Cameron
Journal:  Interdiscip Perspect Infect Dis       Date:  2010-05-25

Review 10.  Severe course of Lyme neuroborreliosis in an HIV-1 positive patient; case report and review of the literature.

Authors:  Nathalie D van Burgel; Mayke Oosterloo; Frank P Kroon; Alje P van Dam
Journal:  BMC Neurol       Date:  2010-11-30       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.